Literature DB >> 8485621

Antiepileptic drug pharmacokinetics and neuropharmacokinetics in individual rats by repetitive withdrawal of blood and cerebrospinal fluid: milacemide.

J Semba1, G Curzon, P N Patsalos.   

Abstract

1. The kinetics and metabolism of milacemide have been studied in an animal model which allows the simultaneous investigation of the temporal inter-relationships of drugs and metabolites in blood (pharmacokinetics) and cerebrospinal fluid (CSF, neuropharmacokinetics) in individual freely moving rats. 2. Milacemide dose-dependently increased CSF glycine and glycinamide (intermediary metabolite) concentrations. This confirms that milacemide is a CNS glycine prodrug. 3. Pretreatment with L-deprenyl (2 mg kg-1), a specific inhibitor of monoamine oxidase type B (MAO-B), almost completely prevented the formation of glycinamide and increased milacemide accumulation in CSF. Tmax and t1/2 were significantly increased and Cmax and AUC values were decreased for glycinamide compared to controls. Pretreatment with clorgyline (5 mg kg-1), a specific inhibitor of MAO-type A, only moderately decreased glycinamide Cmax and AUC values. 4. After milacemide administration (100, 200 and 400 mg kg-1, i.p.) serum and CSF milacemide concentrations rose linearly and dose-dependently. Serum glycinamide concentrations exhibited small dose-dependent rises but these were not linearly related. In contrast, CSF glycinamide concentrations rose linearly and dose-dependently with Cmax values 2.5, 3.2 and 4.1 times greater than the corresponding values for serum glycinamide after giving 100, 200 and 400 mg kg-1 respectively of milacemide. 5. Serum glycine concentrations were unaffected but CSF concentrations increased dose-dependently and these were significant at the higher milacemide doses (200 and 400 mg kg-1). Animals given 400 mg kg-1 milacemide had glycine values which were still significantly elevated 7 h later. 6. In conclusion, serum milacemide rapidly enters and equilibrates with the CNS compartment where it is metabolised primarily by MAO-B to glycinamide and finally to glycine. Metabolism in the peripheral compartment is negligible.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8485621      PMCID: PMC1908144          DOI: 10.1111/j.1476-5381.1993.tb13514.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  39 in total

1.  Glutamatergic therapy of Huntington's chorea.

Authors:  M E Giuffra; M M Mouradian; T N Chase
Journal:  Clin Neuropharmacol       Date:  1992-04       Impact factor: 1.592

2.  An NMDA intervention strategy in schizophrenia with "low-dose" milacemide.

Authors:  R B Rosse; B L Schwartz; R E Davis; S I Deutsch
Journal:  Clin Neuropharmacol       Date:  1991-06       Impact factor: 1.592

Review 3.  Drug metabolizing enzymes in the brain and cerebral microvessels.

Authors:  A Minn; J F Ghersi-Egea; R Perrin; B Leininger; G Siest
Journal:  Brain Res Brain Res Rev       Date:  1991 Jan-Apr

4.  Kinetics of drug action in disease states. XXIV. Pharmacodynamics of diazepam and its active metabolites in rats.

Authors:  P M Klockowski; G Levy
Journal:  J Pharmacol Exp Ther       Date:  1988-03       Impact factor: 4.030

5.  Concurrent monitoring of central carbamazepine and transmitter amine metabolism and motor activity in individual unrestrained rats using repetitive withdrawal of cerebrospinal fluid.

Authors:  E N Sokomba; P N Patsalos; Y I Lolin; G Curzon
Journal:  Neuropharmacology       Date:  1988-04       Impact factor: 5.250

Review 6.  A "glutamatergic hypothesis" of schizophrenia. Rationale for pharmacotherapy with glycine.

Authors:  S I Deutsch; J Mastropaolo; B L Schwartz; R B Rosse; J M Morihisa
Journal:  Clin Neuropharmacol       Date:  1989-02       Impact factor: 1.592

7.  Some puzzling pharmacological effects of monoamine oxidase inhibitors.

Authors:  J Knoll; K Magyar
Journal:  Adv Biochem Psychopharmacol       Date:  1972

8.  Evidence for separate systems for the transport of neutral and basic amino acids across the blood-brain barrier.

Authors:  J J Richter; A Wainer
Journal:  J Neurochem       Date:  1971-04       Impact factor: 5.372

9.  Anticonvulsant activity of milacemide.

Authors:  W van Dorsser; D Barris; A Cordi; J Roba
Journal:  Arch Int Pharmacodyn Ther       Date:  1983-12

10.  Selective acetylenic 'suicide' and reversible inhibitors of monoamine oxidase types A and B.

Authors:  A Kalir; A Sabbagh; M B Youdim
Journal:  Br J Pharmacol       Date:  1981-05       Impact factor: 8.739

View more
  5 in total

1.  Comparison of serum, cerebrospinal fluid and brain extracellular fluid pharmacokinetics of lamotrigine.

Authors:  M C Walker; X Tong; H Perry; M S Alavijeh; P N Patsalos
Journal:  Br J Pharmacol       Date:  2000-05       Impact factor: 8.739

2.  A microdialysis study of glycinamide, glycine and other amino acid neurotransmitters in rat frontal cortex and hippocampus after the administration of milacemide, a glycine pro-drug.

Authors:  M H Doheny; S Nagaki; P N Patsalos
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-07       Impact factor: 3.000

3.  Fasting for 24 h reveals liver microsteatosis after continuous i.v. infusion of milacemide in the rat.

Authors:  J L Rakotoamboa; M Masson; B Palate; J Carleer; J Roba
Journal:  Arch Toxicol       Date:  1994       Impact factor: 5.153

4.  Blood and cerebrospinal fluid pharmacokinetics of primidone and its primary pharmacologically active metabolites, phenobarbital and phenylethylmalonamide in the rat.

Authors:  S Nagaki; N Ratnaraj; P N Patsalos
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1999 Jul-Sep       Impact factor: 2.569

Review 5.  Progress in drug delivery to the central nervous system by the prodrug approach.

Authors:  Barbara Pavan; Alessandro Dalpiaz; Nunzia Ciliberti; Carla Biondi; Stefano Manfredini; Silvia Vertuani
Journal:  Molecules       Date:  2008-05-01       Impact factor: 4.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.